FDA and Medical Product Oversight: Assessing Recent Changes

On June 25, FDA regulatory of counsel Rachel Turow participated in the panel “FDA and Medical Product Oversight: Assessing Recent Changes,” hosted by the Food & Drug Law Institute. The speakers discussed the lasting impact of the reduction in force and subsequent rehiring of staff, a move to “podium policy,” the focus on expedited drug approvals and a deregulatory state.